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Abstract
Several studies have proposed that brain glutamate signaling abnormalities and glial pathology 
play a role in the etiology of major depressive disorder (MDD). These conclusions were primarily 
drawn from postmortem studies in which forebrain brain regions were examined. The locus 
coeruleus is the primary source of extensive noradrenergic innervation of the forebrain and as such 
exerts a powerful regulatory role over cognitive and affective functions, which are dysregulated in 
MDD. Furthermore, altered noradrenergic neurotransmission is associated with depressive 
symptoms and is thought to play a role in the pathophysiology of MDD. In the present study we 
used laser-capture microdissection to selectively harvest locus coeruleus (LC) tissue from 
postmortem brains of MDD patients, patients with bipolar disorder (BPD), and from 
psychiatrically-normal subjects. Using microarray technology we examined global patterns of 
gene expression. Differential mRNA expression of select candidate genes was then interrogated 
using quantitative real-time PCR and in situ hybridization. Our findings reveal multiple signaling 
pathway alterations in the LC of MDD, but not BPD subjects. These include glutamate signaling 
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genes SLC1A2, SLC1A3, GLUL, growth factor genes FGFR3 and TrkB, and several genes 
exclusively expressed in astroglia. Our data extend previous findings of altered glutamate, 
astroglial and growth factor functions in MDD for the first time to the brainstem. These findings 
indicate that such alterations: 1) are unique to MDD and distinguishable from BPD, and 2) affect 
multiple brain regions, suggesting a whole-brain dysregulation of such functions.
Keywords
laser-capture microdissection; human; monoamine; norepinephrine; postmortem; microarray
Introduction
Major depression (MDD) is a chronic and debilitating mood disorder with a 16% lifetime 
prevalence 1 and is associated with excess mortality, especially from cardiovascular disease 
and through suicide 2. Mood disorders, including MDD and bipolar disorder (BPD) are 
characterized by dysfunction of noradrenergic neurotransmission. Drugs that increase brain 
norepinephrine (NE)/serotonin (5-HT) levels act as antidepressants 3, 4, whereas drugs that 
deplete NE/5-HT stores induce a depressive state 5, 6. Currently, most antidepressant drugs 
directly or indirectly target 5-HT and/or NE systems of the brain, as these neurotransmitters 
have been suggested to be mechanistically relevant to the etiology of mood disorders 7. 
However, drugs such as selective 5-HT reuptake inhibitors only produce remission in 37% 
of all patients, and if they show therapeutic responses, then only after 2-5 weeks 8. These 
observations suggest that brain monoamine deficiency may be part of a much more complex 
pathogenesis of major depression that requires further investigation.
The locus coeruleus (LC), which is located in the rostral pontine tegmentum 9, 10, possesses 
the largest number of NE-producing neurons in the mammalian brain. These neurons contain 
the pigment neuromelanin that gives the nucleus its characteristic dark color. LC neurons 
project widely throughout the entire central nervous system, including the cerebral cortex, 
thalamus, septum, hippocampus, hypothalamus, cerebellum, and spinal chord 11-13. In 
addition there are intense reciprocal connections between LC and the 5-HT producing dorsal 
raphe neurons, which provide the basis for neurochemical communication between both 
monoamine systems 14. With their wide-ranging and overlapping projections arising from 
the brainstem, both monoamine systems act in concert to modulate vigilance, sleep-wake 
cycle, memory, adaptive response to stress, and pain modulation 15. These behaviors are 
disturbed in patients with MDD, and as a consequence their LC displays molecular 
abnormalities. Therefore, the current study focused on the locus coeruleus (LC) which 
synthesizes the majority of NE released in the forebrain 16 The study is an attempt to more 
clearly understand the biology of cells in the in the LC (neurons and glia) in depression.
Previous postmortem studies focused on the LC have shown increased protein levels of 
presynaptic alpha 2 adrenoreceptors in MDD, which inhibits the firing of LC neurons and 
subsequent norepinephrine secretion 17. Protein levels of tyrosine hydroxylase, the rate 
limiting enzyme in the synthesis of norepinephrine, are likewise elevated in the LC of MDD 
patients 18, whereas binding to norepinephrine transporter is reduced 19. These results are 
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consistent with the interpretation that: 1) noradrenergic neurotransmission is dysregulated in 
MDD, and 2) the LC represents a key region in the etiology of this disorder. The majority of 
post mortem studies involving the analysis of LC in MDD have focused on analyses of 
proteins involved in noradrenergic neurotransmission. Little is known, however, about 
mRNA expression, especially of non-adrenergic genes, in the LC of MDD patients.
Therefore, in the present study we used gene expression microarray technology in 
combination with laser-capture microdissection (LCM) to profile gene expression in the LC 
from post mortem brains of patients with MDD. These profiles were contrasted to those 
obtained from the LC of BPD patients and psychiatrically-normal subjects. Our approach 
yielded a number of candidate genes that may play a key role in the LC dysfunction in 
depression. Potentially altered gene transcripts were examined using quantitative real-time 
PCR (qPCR) and/or in situ hybridization (ISH). The results implicate MDD-specific 
dysfunctions in glutamate and growth factor signaling with special emphasis on altered 
astroglial transcripts, which is in strong agreement with previous studies from dorsolateral 
prefrontal cortex (DLPFC) and anterior cingulate cortex (AnCg) of MDD patients 20, 21.
Methods
Human Brain Tissue Acquisition and Preparation
All brains used in this study were collected by the Brain Donor Program at the University of 
California, Irvine with the consent of the decendents' relatives. Information regarding 
physical health, medication use, psychopathology, substance use, and details about the final 
hours of the decendents were obtained from medical records, coroner's investigation, 
medical examiner's conclusions, and interviews with relatives. Table 1 lists subjects in the 
current study and includes their age, gender, agonal state, postmortem interval, and brain 
pH. No significant differences in age, brain pH, or postmortem interval among the three 
diagnostic groups were detected (p > 0.05, one-way ANOVA). Previous post mortem studies 
concluded that brain tissue pH and a patient's agonal state (brief vs. protracted deaths) are 
among the most important factors in determining global gene expression patterns 22-24. 
Therefore, the present study only used brain samples with a pH > 6.7, and an agonal factor 
of zero, indicating a brief death.
Brains were removed at autopsy, quickly chilled to approximately 4°C and then cut into 
series of 0.75 cm thick coronal slices that were quickly frozen and stored at -80°C as 
previously described25. Human brain slabs were then placed on dry ice blocks and dissected 
using fine-toothed saw to generate tissue blocks for subsequent cryostat sectioning. Such 
tissue blocks were approximately 4 × 3 cm in size and were stored at −80°C.
Tissue blocks containing LC were cryostat-cut into 10 μm coronal sections at −20°C, 
immediately thaw-mounted onto glass slides (1 section/slide), and then stored at −80° C. 
Every fiftieth section from each subject's slide set was processed for the detection of 
norepinephrine transporter (NET) mRNA via radiolabeled ISH as previously described 26. 
NET mRNA is highly enriched within the boundaries of the LC and can be reliably used to 
map its location 27. Following ISH, slides were stained with luxol fast blue combined with 
cresyl violet to visualize brainstem anatomy. Using these landmarks in combination with 
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shape of the LC (as determined by NET ISH) and NET signal intensity and distribution, 
sections from all subjections were aligned to match along the anterior-posterior brain axis.
We used the ISH signal obtained from neighboring sections as guide to microdissect the LC 
by the means of laser capture (ISH-guided LCM). For each subject we collected a total of 4 
slides 500 μm apart from within a 2 mm common region of the mid-rostral portion of the 
nucleus (~ +25 to +27 mm from obex 28), which resulted in processing of 8 bilateral LCs. 
Selected slides were removed from −80° C, thawed for 30 sec at room temperature, then 
dehydrated and defatted as previously described 29. ISH-guided LCM procedure was used to 
microdissect individual LC nuclei which is described in detail elsewhere 26.
RNA isolation and amplification
RNA isolation, including DNAse treatment, was performed using the PicoPure RNA 
Isolation kit (Molecular Devices, Sunnyvale, CA) according to the manufacturer's protocol. 
The final RNA elution volume was 15 μl. To assess RNA quality and concentration, 1 μl of 
each subject's isolated RNA sample was evaluated with on a 2100 BioAnalyzer (Agilent 
Technologies, Palo Alto, CA) and resulting electropherograms were quantified according to 
the method of Schoor et al. 30. This method has been applied to human brain tissue obtained 
through ISH-guided LCM 26.
RNA samples were subject to two rounds of RNA amplification (RiboAmp OA RNA kit, 
Molecular Devices). After the first round of amplification a portion of amplified double-
stranded cDNA was saved for qPCR. Following two amplification rounds, 15 μg of 
biotinylated amplified RNA from each subject was then hybridized to HG-U133 Plus 2.0 
arrays (Affymetrix, Santa Clara, CA) per manufacturer's instructions.
Microarray data analysis
Robust Multi-Chip Average (RMA) and Affymetrix Microarray Suite 5 (MAS5) calls 
algorithms were employed for Affymetrix CEL files analysis. Affymetrix chip description 
files were replaced by a custom probe set mapping files (http://
brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/
genomic_curated_CDF.asp), which independently reassigned all Affymetrix probe sets to an 
updated UniGene cluster (Build No. 199). Log 2-transformed intensity values of all 
transcripts from RMA output were statistically analyzed using Microsoft Excel 2003 
software (Microsoft, Redmond, WA). Disease specific gene expression differences from 
controls were evaluated using Student's t-tests. Genes were considered to be significantly 
altered if: (1) the p values were ≤ 0.05, (2) the mRNA was detected in ≥ 50% of arrays in C, 
BPD, or MDD groups according to MAS5CALLS algorithm, and (3) a gene's log2 intensity 
value was ≥4 according to RMA algorithm. Pairwise fold change differences were 
calculated from group means of microarray intensity values. Pearson correlation calculations 
(two-tailed p-values) between microarray and qPCR data were made with GraphPad Prism 4 
software (Graphpad, La Jolla, CA).
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Canonical Pathway Analysis
Canonical pathway analysis was generated through the use of Ingenuity Pathways Analysis 
(Ingenuity® Systems, Redwood City, CA). Microarray data were filtered to only include 
genes that: a) had log2 intensity value of ≥4; b) were detected on at least 50% of microarrays 
in any of the diagnostic groups; and c) had Student t-test p-values of ≤0.1 for either MDD 
vs. Control or BPD vs. Control comparisons; and d) and were altered in their mRNA 
expression either ≤ −1.05 or ≥1.05- fold. These relaxed parameters were used to maximize 
the number of candidate genes for downstream analyses. To investigate potential 
involvement of different functional pathways selected candidate genes were evaluated using 
Canonical Pathway analysis tool in the Ingenuity Pathways Knowledge Base (Ingenuity 
Pathways Analysis software (IPA), Ingenuity® Systems, www.ingenuity.com) The 
significance of the association between these data sets and each canonical pathway was 
evaluated using: 1) a ratio of the number of genes in the data set that belonged to a particular 
pathway relative to the total number of genes in such canonical pathway and 2) a p-value 
(Fischer's exact test) to determine the probability that the association is due to chance.
Quantitative Real-Time PCR (qPCR)
QPCR confirmation of microarray results utilized SYBR Green chemistry. A Bio-Rad 
iCycler (BioRad, Hercules, CA) along with SYBR-488 detection protocol combined with a 
touchdown PCR approach 26, 29 was employed for performance of amplification reactions 
and fluorescence quantification. Reactions were performed in 96 well PCR plates (Bio-Rad) 
with each well containing 5 μl of amplified double-stranded cDNA (aDNA; 50 pg/μl) that 
was set aside following the first round of RNA amplification. The concentration of aDNA 
was quantified for each sample using Quant-iT PicoGreen dsDNA kit (Invitrogen, Carlsbad, 
CA) according to manufacturer's instructions. To each well 5 μl of forward and reverse 
strand primers (final concentration: 500 nM) and 10 μl of iQ SYBR Green Supermix (Bio-
Rad) were added. Amplifications of all samples were carried out in triplicate and the average 
cycle threshold (Ct) was then calculated for each sample. Replicates that were ≥1 Ct away 
from the mean Ct were excluded; the mean Ct was calculated from the remaining duplicates. 
Subjects with only one Ct value were excluded from further analysis. Because input amount 
of aDNA was equivalent across all samples, raw Ct values were inversely proportional to the 
intensity levels of gene expression. We chose this approach rather than the ΔΔCt method, 
which relies on normalization to housekeeping genes, because of the potential for 
differential mRNA expression of such reference transcripts 31, 32. A similar approach in 
which standardized DNA input amounts for qPCR were used has recently been validated 26, 
33
.
The following formula was used to calculate relative fold changes: 2−(Cta − Ctb) in which Cta 
is cycle threshold in experimental subjects (MDD or BPD) and Ctb is cycle threshold in 
control subjects. The specificity of each reaction was then confirmed by the presence of a 
single peak on the melting curve, plotted as the negative derivative of fluorescence during 
incremental increases in well temperature. No template controls, in which aDNA was 
replaced with distilled H2O, did not yield amplification products. Primer design details are 
described elsewhere 26. Sequences of PCR primer pairs used in the present study are listed 
in Table S1.
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In Situ Hybridization (ISH)
Detailed ISH methods using postmortem human brain tissue have been described elsewhere 
34
. Briefly, slides adjacent to the ones used for LCM were removed from -80°C storage, 
fixed in 4% paraformaldehyde at room temperature, rinsed in standard saline citrate buffer, 
incubated in a solution containing acetic anhydride in triethanolamine, and dehydrated in 
aqueous solutions with increasing alcohol concentrations. Sections were then hybridized 
with 35S-UTP- and 35S-CTP-doublelabeled cRNA probes, produced using standard in vitro 
transcription methodology. Riboprobes for NET (NM_001043) pos.1-1974 and TH 
(NM_000360) pos. 336-734 were synthesized from human cDNA fragments cloned in 
house. Clones for probes of glutamate-ammonia ligase (glutamine synthetase; GLUL/
GLNS), solute carrier family 1 (glial high affinity glutamate transporters) members 2 and 3 
(SLC1A2, SLC1A3) were a kind gift from Dr. Choudary (University of California – Davis). 
Probe sequences and information regarding their specificities have been previously 
published 20.
Following overnight incubation at 55°C, slides were washed, rinsed, dehydrated, and 
exposed to Kodak Biomax MR film (Eastman Kodak, Rochester, NY, USA). Exposure time 
was empirically determined using test slides to optimize the specific signal for densitometric 
analysis. Specificity of the hybridization was confirmed in control experiments using sense 
riboprobes.
Quantification of the Radioactive Signal
ISH autoradiograms were digitized and captured using ScanMaker 1000XL Pro Flatbed 
Scanner (Microtek, Carson, CA) in combination with SilverFast Ai Imaging Software 
(LaserSoft Imaging, Inc., Sarasota, FL). Adobe Photoshop CS software (Adobe Systems, 
San Jose, CA) was used to import images of adjacent autoradiograms labeled for TH, 
SLC1A2, SLC1A3, and GLUL mRNAs into individual layers. These digitized images were 
overlaid in Photoshop and registered to each other using major anatomical landmarks in 
each image as guides. Afterwards, 4 individual layers consisting of aligned TH, SLC1A2, 
SLC1A3, and GLUL autoradiogram images were imported into ImageJ software, version 
1.37 (rsbweb.nih.gov/ij/) 35. In the TH autoradiogram anatomical boundaries of LC were 
identified, outlined, and transferred to the exactly matching position in the SLC1A2, 
SLC1A3, and GLUL labeled images where optical density within the whole area of the LC 
(as defined by TH mRNA distribution) was measured. Gray scale values were converted 
into relative optical density (ROD) measurements using standards from an optical density 
step tablet. Background was measured and subtracted from each specific LC measurement. 
Mean ISH signals were statistically analyzed using one-tailed Student's t-tests in Prism 4.0 
software (GraphPad). Pearson correlation coefficients (two-tailed p-values) of ISH signals 
and qPCR Ct values were also computed with Prism 4.0 software (GraphPad).
Results
RNA quality
RNA quality was assessed by evaluating electropherogram signals prior to the appearance of 
the 18S peak and the AUC of the 28S peak. RNA samples with less than 65% of their total 
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signal in the pre-18S peak area of the electropherogram and more than 4% of total signal 
under the 28S peak have been demonstrated to produce accurate and reliable results in 
microarray- and qPCR-based gene expression experiments 26, 30. Such analysis of our 
samples showed that the pre-18S peak area contained: 47.9±1.7% (Control), 47.8±1.4% 
(MDD), and 48.9±2.7% (BPD) of total signal, while the 28S peak region contained: 
11.8±1.0% (Control), 10.8±0.9% (MDD), and 12.0±1.7% (BPD) of total signal. For 
technical reasons we are unable to obtain these parameters in three (1 control, 2 MDD) of all 
27 samples. However, downstream gene expression results were not significantly different 
in these three samples. Our results indicate that the RNA extracted from all samples was 
suitable for valid analysis of microarray- and qPCR based gene expression data 26, 30
Overall Microarray results
Averaged microarray array intensity values derived from log2 RMA data were as followed 
(mean±S.E.M.): 6.75± 0.02 (control); 6.76± 0.04 (MDD); 6.77± 0.02 (BPD). Raw detection 
call rates calculated from the MAS5CALLS output were (mean±S.E.M.): 46.1 ± 0.9% 
(control); 45.0 ± 1.2% (MDD); 46.6 ± 0.4% (BPD). There were no significant differences 
(p>0.05) among diagnosis groups for RMA or MAS5CALLS, indicating an overall 
expression homogeneity among groups.
Glutamate signaling gene transcripts exhibit altered mRNA expression in LC of MDD 
subjects
Comparing mood disorder groups, microarray data revealed that at p≤0.1 significance level 
1094 and 695 genes transcripts were upregulated in MDD and BPD patients, respectively, 
whereas 474 transcripts in MDD and 454 transcripts in BPD were downregulated. We 
utilized Ingenuity pathway analysis (IPA) as a discovery science approach for examination 
of LC microarray and for the identification of significantly altered canonical pathways. The 
pathway that was most significantly (p=0.004) altered in MDD was the one for glutamate 
signaling (Figure 1). It is defined by 47 different genes, and we found significantly altered 
mRNA expression in 8 of such genes. Of these 8 genes three were downregulated, in their 
mRNA expression and consisted of transcripts that encode high affinity glutamate 
transporters SLC1A2 and SLC1A3, and GLUL, are all of which are specifically expressed in 
glial cells but not in neurons. In contrast, 4 of the post-synaptic glutamate receptor 
transcripts were upregulated – GRIA1, GRIK1, GRM1, GRM5, whereas the presynaptic 
vesicular glutamate transporter 2 (VGLUT2 or SLC17A6) was upregulated in its gene 
expression as well. Of the eight altered glutamate signaling genes in MDD, which are all 
individually altered at the alpha level of p<0.05, only GRM5 also exhibited significant 
transcript upregulation in BPD subjects.
Subsequently, four glutamate signaling genes transcripts were probed using qPCR. This 
approach confirmed microarray results for the transcripts SLC1A2, SLC1A3, and GLUL 
whereas VGLUT2 transcript did not show altered mRNA expression (Table 2).
Because of their profound impact on synaptic glutamate clearance SLC1A2, SLC1A3, and 
GLUL were selected for additional validation with ISH performed on sections adjacent to 
those used for LCM. Representative examples of LC ISH autoradiogram images are shown 
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in Figure S1. In MDD subjects ISH optical density for SLC1A3 and GLUL was significantly 
decreased whereas the decrease in optical density for SLC1A2 did not reach statistical 
significance (Table 2). For BPD subjects no statistical significant ISH density changes were 
observed. Mean GLUL and SLC1A3 ISH ROD values for each subject are significantly 
correlated with their respective qPCR cycle threshold values (Table 3B). These results are 
consistent with the interpretation that the gene transcripts for SLC1A3 and GLUL are 
downregulated in MDD, confirming microarray and qPCR results.
Glial deficits accompany glutamate signaling alterations in MDD
Since we detected that the strongest gene expression changes of glutamatergic transmission 
transcripts have glial origin, we hypothesized that there may be a general deficit of glial 
function. To test this notion we specifically examined mRNA expression of other genes 
known to be exclusively expressed by glia. This analysis revealed significant reductions in 
the mRNA expression of such transcripts, including GFAP, S100B, GJA1, GJB6, and AQP4 
in MDD but not BPD subjects. QPCR experiments confirmed these gene expression changes 
(Table 2) and individual microarray and qPCR results for all glia-associated genes are 
strongly correlated (Table 3A, Figure S2). In contrast, mRNA expression of genes 
exclusively expressed in neurons, such as NEFL, NEFM, NEF3, and ENO2 were not altered 
in MDD or BPD, according to microarray results. The ENO2 transcript was then additional 
probed using qPCR, which confirmed microarray results. ENO1, a non-neuronal marker, 
displayed no microarray or qPCR gene expression differences in MDD and BPD. Taken 
together, these results suggest that there may be a selective insult to LC glial function in 
MDD.
Growth factor transcripts display altered gene expression in MDD
Finally we examined the mRNA expression of gene transcripts, which have been previously 
shown to be dysregulated in MDD specifically those that regulate FGF and BDNF functions 
as both have been implicated in the pathophysiology of MDD 21. Microarray gene 
expression of neurotrophic tyrosine receptor kinase receptor 2 (TrkB) and fibroblast growth 
factor receptor 3 (FGFR3) was significantly downregulated in the LC of MDD and were 
confirmed by qPCR. Additionally, the receptor ligands displayed altered microarray gene 
expression with FGF2 being downregulated whereas FGF9 as well as insulin-like growth 
factor 1 (IGF1) were upregulated. However, these microarray results were not confirmed by 
qPCR. All observed growth factor transcript alterations were specific to MDD subjects.
Discussion
The present study examined alterations in gene expression in the LC of patients with 
antemortem diagnosis of either MDD or BPD as compared to psychiatrically-normal 
subjects. We chose ISH-guided LCM to dissect tissue from individual LC nuclei, because 
our previous study has shown that this approach, compared to micropunches, provides 
increased anatomical resolution and more precise sampling which enriches specific mRNAs 
and thus improves sensitivity and the dynamic range of microarray-based gene expression 
profiling 26. Rather than individual LC cells, we laser-dissected the entire LC area to obtain 
transcriptional information from neurons and glia, as all cell types within a brain nucleus 
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form a functional, and signaling network. While previous studies focused on neurons in the 
LC, recent studies have emphasized the importance and vulnerability of glia in mood 
disorders, such as major depression 20, 39, 40. Our initial studies were performed using high-
density oligonucleotide microarrays in an unbiased discovery science approach to uncover 
potential alterations in the mRNA expression of functionally related genes. Changes in 
mRNA expression of selected candidate gene transcripts were then validated with qPCR and 
ISH. Based on microarray results, we thereby focused our efforts on genes that directly 
interface between astrocytes and components of glutamate signaling pathway. Our data 
indicate that several classes of genes were differentially expressed in MDD subjects, 
including those involved in: glutamate neurotransmission, glial function, and growth factor 
signaling. In contrast, none of these functional groups exhibited altered gene expression in 
the LC of BPD patients. These results suggest that dysregulation in these signaling systems 
in the LC may contribute to pathophysiological changes in MDD.
Limitations
The results presented here do not reflect gene expression alteration of the entire locus 
coeruleus. After alignment of LC-containing brain sections from all subjects, the mid-rostral 
portion of the LC was sampled. This region is known to send projections to many forebrain 
structures including hippocampus, cortex and hypothalamus 11-13; The functions of these 
regions are thought to be compromised by major depression. A MRI study has shown that 
neuromelanin signal intensity was selectively reduced in the medial and rostral part in locus 
coeruleus in depression in patients with major depression, implicating noradrenergic 
dysfunction 41. However, a previous postmortem study found no difference in 
neuromelanin-containing cells between control and major depressive subjects at any level of 
the LC 42.
Several postmortem studies have investigated LC nuclei of MDD patients for altered protein 
levels and found elevated immunoreactivity of TH 18, 42, nNOS 43, CRF 44 and reduced 
binding to NET 19. Our results, however, did not show mRNA expression changes of TH, 
CRF, and NET in the LC of MDD or BPD subjects. In fact, none of the transcripts of the 
norepinephrine biosynthesis enzymes exhibited gene expression alterations in MDD or BPD 
(data not shown). Translational regulatory mechanisms at the protein level may be 
responsible for these discrepancies.
We observed significant differences in the mRNA expression of glial and glutamatergic 
transcripts in MDD, but not BPD subjects. This observation may indicate that such changes 
are specific to MDD; however, it is limited by the small number of BPD subjects. However, 
our power analysis calculations indicate that given effects and associated variability 
significantly larger number of BPD subjects would be required to replicate observed gene 
expression alterations in MDD. For example, for SLC1A3, SLC1A2, and GLUL gene 
expression as measured by qPCR, power analysis calculations predict that 14, 15, and 12 
MDD subjects respectively, would be required to observe differences vs. Controls at the p < 
0.05 level. On the other, hand for BPD vs. Control comparisons 143, 159, and 90 BPD 
subjects would be required for each gene to observe the same effects. Similarly, we 
observed large differences (ranging from 2- to over 100- fold) in the power calculations for 
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potential effects in MDD and BPD groups for all of the other transcripts we assayed by 
qPCR, including: FGF-2, FGF-9, FGF-R3, TrkB, SLC17A6, GFAP, S100B, GJA1, GJB6, 
AQP4, and ENO1. In our future studies we plan to increase the number of BPD subjects to 
confirm the specificity of these findings to MDD.
Most of the MDD subjects included in this study died from suicide, which was very likely 
related to their mood disorder. Therefore, the observed changes in LC gene expression 
described here may not apply to mildly to moderately depressed patients but may be limited 
to severely depressed, suicidal patients.
Gene expression alterations in glutamate signaling and glial genes in the LC of MDD may 
be functionally and anatomically related
Several human MRI studies have linked altered brain glutamate levels and major depression 
45
, 
46
 and have shown that therapeutic intervention can normalize brain glutamate 
concentrations 46, 47, which in turn lessens the severity of depressive symptoms. 
Glutamatergic neurons, mainly originating from the nucleus paragigantocellularis, provide a 
major excitatory input to the locus coeruleus 48. A second region, the medial prefrontal 
cortex, can also elicit glutamatergic responses in the LC 49. Glutamate exerts its 
postsynaptic activity through a variety of ionotropic and metabotropic glutamate receptors in 
the LC. Studies in rhesus monkey showed that the LC mainly expresses mRNA subunits for 
AMPA, GRM3. GRM1 and, GRM5 50. Local LC administration of AMPA elicits 
norepinephrine release from the LC 51 suggesting that glutamate in LC drives 
norepinephrine turnover. Excess levels of glutamate acting via glutamate receptors can 
cause neuronal damage (reviewed in 52) and is hypothesized to contribute to depression. 
Conversely, several antagonists of NMDA receptors have antidepressant properties 
(reviewed in 53). To prevent glutamate excitotoxicity, the glutamate transporters SLC1A2 
and SLC1A3 take up excess glutamate into glia. Knockdown of glia glutamate transporters 
induces glutamate toxicity, whereas genetic deletion of neuronal glutamate transporters does 
not 54, 55. This emphasizes the physiological importance of glial glutamate transporters as 
the main source to prevent neuronal damage from excess glutamate.
The results presented here are in agreement with the existing hypothesis of altered glutamate 
neurotransmission in major depression. We found that the glutamate signaling pathway was 
the most significantly altered canonical pathway in the LC of MDD patients implying that 
altered mRNA expression of several glutamate signaling genes significantly impacts the 
signaling of the entire glutamate pathway. Expression of glutamate signaling genes was 
altered in different compartments of the LC synapse. The largest and qPCR-confirmed 
mRNA expression changes of glutamate signaling genes were limited to genes transcripts 
exclusively expressed in glia cells, including the two glia high affinity glutamate 
transporters SLC1A2 and SLC1A3. In situ hybridization also confirmed the downregulation 
of the SLC1A3 transcript. Both transporters play a crucial role in terminating glutamatergic 
neurotransmission by glial glutamate uptake and thereby maintaining synaptic glutamate 
concentrations. Glutamate transporters can concentrate glutamate more than 106-fold across 
cell membranes 56 to protect neurons from glutamate excitotoxicity 57.
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Pharmacological enhancement of glial glutamate transporter function has antidepressant 
effects in humans 58 and in mouse models of depression 59. In addition to glutamate 
transporters, the gene expression of the enzyme that converts glutamate to glutamine, 
GLUL, also exhibited decreased mRNA expression in the LC of MDD patients. Gene 
expression of SLC1A2, SLC1A3, and GLUL have been shown to be significantly decreased 
in the anterior cingulated and dorsolateral prefrontal cortex of MDD patients 20. GLUL gene 
expression is also downregulated in the inferior frontal gyrus of depressed suicide victims 
60
. Downregulation of these three important glutamate signaling may not only perturb the 
balance between excitatory and inhibitory neurotransmitters but it can lead to cytotoxic 
glutamate concentrations affecting nearby neurons and glia 61. Our results show that several 
markers of glia, not of neurons, show strongly reduced mRNA expression in the LC of 
MDD patients (Table 2), suggesting glial dysfunction in the LC of MDD, but not BPD 
patients. Similar glia-linked glutamate signaling impairments were recently reported in a rat 
model of depression 62. Glia cells not only regulate and replenish the synaptic glutamate 
pool but glia also exchange signaling molecules with neurons and release neurotransmitters, 
including glutamate, to regulate the strength of synapses 63. Several postmortem studies 
have demonstrated reduced glial cell number and glial density in cortical and limbic brain 
regions of depressed subjects 39, 64-67. In our study, the non-neuronal marker ENO1 shows a 
trend (p=0.1, FC=−1.3) towards reduced gene expression in qPCR experiments, whereas 
mRNA expression of the astrocyte marker GFAP is significantly reduced in microarray and 
qPCR gene expression experiments in MDD subjects only (Table 2). This finding suggests 
that the observed gene expression changes of glial marker genes may reflect transcript 
expression alterations in astrocytes specifically. This notion is supported by the fact that 
nearly all glia transcripts in our study with significantly decreased mRNA expression in 
MDD subjects are mainly expressed in astrocytes 68-70. These include several signaling 
members that are crucial for astroglia function, such as GJA1, GJB6, S100B, and AQP4 all 
of which show strongly reduced mRNA expression in MDD subjects. GJA1 and GJB6 form 
astrocytic gap junctions, which form large molecule-permeable hemichannels providing 
high-conductance communication pathways between adjacent glia cells that are necessary 
for the propagation of ATP-induced Ca2+ waves among neighboring astrocytes 71. S100B is 
a peptide produced by CNS astroglia acting as trophic factor to promote axonal growth and 
synaptic remodeling 72. S100B for some time has been implicated in major depression 73 
and its transcript has been recently shown to be downregulated in the orbitofrontal cortex of 
suicide victims with a history of major depression 60.
Recent reports of differential astrocytic distribution of glutamate transporters and receptors 
suggest that astrocytes form different subpopulations. In mouse hippocampus it has been 
shown that of these subgroups only astrocytes that express glutamate transporters participate 
in a gap junction network 74. Gap junction uncoupling of cultured cortical astrocytes is 
associated with a substantial loss in SLC1A2 gene expression and reduced glutamate uptake 
75
. In addition, the water transport regulating channel AQP4 is not only co-localized with 
SLC1A2 but loss of AQP4 function downregulates glutamate uptake and SLC1A2 gene 
expression in cultured astrocytes 76. Thus, the strong concomitant decreases in gene 
expression of glutamate transporters and their co-localized astrocytic constituents in MDD 
subjects in the present study suggest a structural and functional linkage between glutamate 
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transporters, gap junctions, and aquaporin-4 channels and point to an overall glial deficit in 
the LC of MDD patients. Whether the reduced mRNA expression of these astroglia genes is 
accompanied by glia-related histological or morphological alterations in the LC needs to be 
investigated.
Neurotrophic receptor gene expression deficits in MDD as observed in the cortex are also 
present in the LC
Neurotrophic growth factors, such as BDNF and FGF-2, regulating neuronal plasticity, 
survival, and axonal growth, have been implicated in the pathophysiology of major 
depression 77. Centrally administered BDNF produced antidepressant effects in animal 
models of depression 78. Antidepressants have previously been shown to increase BDNF 79, 
80
 and FGF-2 81 levels and both growth factors promote and mediate antidepressant and 
anxiolytic effects in rodents 82-84. Conversely, gene expression of some FGF-ligands and -
receptors 21 and the BDNF receptor TrkB is downregulated in the AnCg, DLPFC, and 
hippocampus of depressed and suicidal subjects 21, 85. Our results are in strong agreement 
with these findings. LC microarray gene expression of growth factors FGF-R3 and TrkB 
receptor was decreased, whereas the FGF receptor ligand FGF-9 was upregulated (Table 2). 
This replicates the gene expression pattern observed in AnCg and DLPFC of MDD subjects, 
suggesting that similar growth factor dysregulation mechanisms may exist in multiple brain 
regions of the depressed patients. In addition our study revealed that the growth factor 
transcript IGF-1 was upregulated in LC of MDD subjects. This is consistent with the 
findings that IGF-1 serum levels are increased in MDD patients, and that IGF-1 
concentrations only decrease in responders to fluoxetine treatment 86.
Conclusion
In summary, the present study is the first to use laser-capture microdissected LC from mood 
disorder patients for gene expression profiling. The results show that several gene families, 
such as glutamate signaling genes, growth factor genes, and astrocytic genes, which have 
been previously shown to display altered mRNA expression in forebrain of MDD patients or 
suicide victims 20, 21, 60, are altered as well in LC of depressed subjects. However, also 
novel candidates such as gap junction genes exhibit a strongly reduced gene expression in 
MDD only. The results suggest that glutamate and astrocyte gene expression abnormalities 
in MDD are functionally linked and may contribute to the perturbation of the LC 
noradrenergic function. Whether the gene expression changes of glutamate and glia 
signaling genes reflect underlying pathophysiological changes or simply a diminished 
presence of certain glia constituents needs to be determined. Recent studies support the 
concept of altered glutamate transporter function in MDD 58.
Future experiments will need to stereologically quantify glia and neurons in the LC of MDD 
subjects to determine whether the ratio of glial cells to neurons is altered in patients with 
MDD. Equally important are studies designed to test whether the transcriptional gene 
expression chances in the LC of MDD patients are also found in corresponding translated 
proteins. LCM of single neurons and glia cells of the LC might be valuable tool to gain 
deeper insight in the signaling abnormalities in MDD in order to improve treatment options 
for mood disorders.
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Figure 1. 
Synaptic location of elements of canonical glutamate signaling pathway. Model of glutamate 
synapse consisting of pre- and postsynaptic neuron and glial cell depicting the cellular 
location of key glutamate signaling and interacting proteins according the IPA knowledge 
base. Marked in green are gene products that are downregulated, whereas highlighted in red 
are upregulated gene products in the LC of MDD patients.
Abbreviations: CALM – calmodulin; HOMER – homer homolog; Gβγ – beta/gamma 
subunit of G protein coupled receptor; GLNS – glutamine synthetase; GLS – glutaminase; 
GRIA – glutamate receptor, ionotropic AMPA; GRID – glutamate receptor, ionotropic, 
delta; GRIK – glutamate receptor, ionotropic, kainite; GRIN - glutamate receptor, 
ionotropic, NMDA; GRIP – glutamate receptor binding protein; GRM –glutamate receptor, 
metabotropic; PICK1 – protein interacting with C kinase 1; PSD-95 – postsynaptic density 
protein 95; SLC – member of solute carrier family
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Table 3
Correlation between gene expression validation methods for differentially expressed genes. Table A) Pearson 
correlations between microarray and qPCR expression data with correlation-associated p-values for C, MDD, 
and BPD subjects. Table B) Pearson r correlations between qPCR expression and ISH signal intensity data 
with correlation-associated p-values for C, MDD, and BPD subjects.
A
Gene Pearson r p value
AQP4 0.750 <0.0001
FGFR3 0.697 <0.0001
GFAP 0.492 0.0091
GJA1 0.906 <0.0001
GJB6 0.852 <0.0001
GLUL 0.741 <0.0001
OXTR 0.743 <0.0001
S100B 0.748 <0.0001
SLC1A2 0.860 <0.0001
SLC1A3 0.766 <0.0001
TrkB 0.725 <0.0001
B
Gene Pearson r p value
GLUL 0.461 0.036
SLC1A2 0.417 0.085
SLC1A3 0.661 0.001
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